Les bonnes nouvelles de Viaskin Peanut

03:34 EDT 3 Aug 2017 | Biotech-Finances

Tous les jours un bref écho des principales infos de la veille avec le remindHIER de BiotechFinances DBV Technologies (FR0010417345 – DBV), annonce le début du recrutement de son étude EPITOPE (EPIT in TOddlers with PEanut Allergy), un essai clinique international de phase III évaluant l’innocuité et l’efficacité de Viaskin Peanut dans le traitement de patients âgés de 1 à 3 ans atteints d’allergie à …

Cet article Les bonnes nouvelles de Viaskin Peanut est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Les bonnes nouvelles de Viaskin Peanut


More From BioPortfolio on "Les bonnes nouvelles de Viaskin Peanut"

Quick Search

Relevant Topics

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...